Literature DB >> 12115087

Injection drug use facilitates hepatitis C virus infection of peripheral blood mononuclear cells.

Massimo Resti1, Chiara Azzari, Maria Moriondo, Letizia Betti, Idanna Sforzi, Elio Novembre, Alberto Vierucci.   

Abstract

Infection of peripheral blood mononuclear cells (PBMCs) with hepatitis C virus (HCV) has been demonstrated and has been found to play a role in relapse of HCV disease and vertical transmission of HCV. Injection drug use is thought to impair function of the immune system and induce tolerance to viruses; therefore, HCV infection of PBMCs could be more likely to occur in injection drug users (IDUs) with HCV infection. Of 108 women who tested negative for human immunodeficiency virus type 1 and positive for HCV RNA, 51 had a history of injection drug use and 57 had no known risk factor for HCV infection. HCV infection was found, by nested reverse-transcription polymerase chain reaction analysis, in the PBMCs of 33 IDUs and of 13 non-IDUs (P=.00003). No correlation was found between infection of the PBMCs and HCV genotype or virus load. Route of transmission and viral factors, as well as immunologic dysfunction, may play a role in viral tropism.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12115087     DOI: 10.1086/341302

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  3 in total

1.  Negative-strand hepatitis C virus (HCV) RNA in peripheral blood mononuclear cells from anti-HCV-positive/HIV-infected women.

Authors:  Tomasz Laskus; Eva A Operskalski; Marek Radkowski; Jeffrey Wilkinson; Wendy J Mack; Marina deGiacomo; Lena Al-Harthi; Zhi Chen; Jiaao Xu; Andrea Kovacs
Journal:  J Infect Dis       Date:  2006-11-27       Impact factor: 5.226

Review 2.  Hepatitis C in pregnancy.

Authors:  Grace L Su
Journal:  Curr Gastroenterol Rep       Date:  2005-02

Review 3.  Human cell types important for hepatitis C virus replication in vivo and in vitro: old assertions and current evidence.

Authors:  Dennis Revie; Syed Zaki Salahuddin
Journal:  Virol J       Date:  2011-07-11       Impact factor: 4.099

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.